Selective COX-2 inhibition improves endothelial function in coronary artery disease - Wikidata - wikimedia - TriplyDB

Selective COX-2 inhibition improves endothelial function in coronary artery disease

Selective COX-2 inhibition improves endothelial function in coronary artery disease

http://www.wikidata.org/entity/Q28194726

about

sameAs

Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis Acute coronary disease Athero-Inflammation: Therapeutic approach Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population The safety of rofecoxib Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance C-reactive protein (CRP)-lowering agents Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease.The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study.Oleocanthal, a phenolic derived from virgin olive oil: a review of the beneficial effects on inflammatory disease Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation.The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame.Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia.C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents Vasomotor Reaction to Cyclooxygenase-1-Mediated Prostacyclin Synthesis in Carotid Arteries from Two-Kidney-One-Clip Hypertensive Mice.Cardiovascular effects of selective cyclooxygenase-2 inhibitors.Src Tyrosine Kinase Activation by 4-Hydroxynonenal Upregulates p38, ERK/AP-1 Signaling and COX-2 Expression in YPEN-1 Cells.Cardiovascular risk and COX-2 inhibition in rheumatological practice.Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.Accelerated atherosclerosis in inflammatory rheumatic diseases.Spatial and temporal dynamics of the endothelium.Life after Vioxx: the clinical implications.Selective COX-2 inhibitors and risk of myocardial infarction.Cardiovascular effects of coxibs.Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?Endothelial biomedicine: its status as an interdisciplinary field, its progress as a basic science, and its translational bench-to-bedside gap.Test-retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design.Cardiovascular risks of cyclooxygenase inhibition.Oxidative stress-dependent cyclooxygenase-2-derived prostaglandin f(2α) impairs endothelial function in renovascular hypertensive rats.Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.Cyclooxygenase products and atherosclerosis VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS.Increased superoxide and endothelial NO synthase uncoupling in blood vessels of Bmal1-knockout mice.

P2860

Q21195404-C23C383D-E75B-4851-89C2-630B9E29EE28 Q24793068-36A10161-9783-43E4-B4BA-5EFCBC917699 Q26774109-721D3806-B0A8-44FE-8955-2F3BBFB97DF3 Q28176535-CC5B224D-3064-40D3-9FC5-2DC7F624252C Q28184682-B43048DA-DA03-42A4-8D6C-4984EF9B6416 Q28191924-629E70B1-417E-4674-B2C0-8EBEFF734053 Q28200344-9D8B3F91-93B2-45C8-83CA-17993CA4A9EF Q28222097-FB798A1E-0D97-4089-955B-B4113D59386C Q33760484-5896E055-85F1-4F52-93C7-D4568DA23877 Q33848290-FFE17BEF-5218-4D42-8E38-EA2B78E58430 Q34072400-BF287001-E256-4C6B-84F4-5FFB2BFCDF7E Q34109302-D2CF86EF-CB7D-4BA8-8423-D2F49699088B Q34636574-C2388BAB-5EFB-4964-8353-2EA97DEC66E4 Q35099836-029678FA-8ED0-445B-97C2-0E94318E31DE Q35152176-94D5FC34-1D8F-4BF7-85AB-818B4C74C52C Q35167284-001FF344-279A-483D-8400-66F72089913D Q35376020-86FCF641-8C2C-4677-AFF4-CCCC14C0573F Q35636594-10380DDB-49B4-4E27-99C9-93EFCA66FA5D Q35648213-63182C47-3867-46AB-B853-8E07CA86E453 Q35755897-5DC12866-5F78-47D2-B460-1EE7A170EBA9 Q35777371-EDCDDC6B-FC8A-4E5C-BB63-56BF77E8D346 Q35806907-F3527A23-BAE3-4DF4-A298-3462E5B4068B Q35896154-077CB30A-07A7-4818-AF05-7F51370EE7DD Q35921247-E04A99D3-D1E6-4A6E-9C10-34C125FF61E9 Q35932689-AB09DD67-4614-44AD-ABA7-4821C84A9C3C Q36126944-AED0CE53-C33D-4B51-8448-52375E7920C6 Q36141793-4303049B-73D1-4C8C-8448-299CD156DFBF Q36173750-3F58602F-DAE0-445E-AF8B-139B90C1629F Q36283528-51E71A19-3005-46DC-957E-F4922A8D9A23 Q36304331-4AB96F0C-1D1A-42E0-8DFD-822E862B9A54 Q36314380-445B8041-AB50-44A5-BA88-06B52E50536A Q36441596-FEE78128-2622-4845-A607-BE14E3FF1847 Q36520638-33551019-D239-4009-96BE-6548F39D8DF8 Q36645351-2F516CB9-0B24-4B7C-9487-B858A518EA84 Q36645806-EB385512-835B-4FCA-AC64-BEAD998ACEFA Q36673018-E00E795F-3958-4290-BDE3-855E1F529AD4 Q36761358-BE7BC2B2-5661-43BC-AD85-D6C6E7385037 Q37071164-02140318-0168-4976-8796-B9907208D6C0 Q37077297-CCC6E04B-8333-4E85-BD48-3CEB10FB0954 Q37088422-81906193-94AA-4326-9491-E68B9E2EDDAA

P2860

Selective COX-2 inhibition improves endothelial function in coronary artery disease

http://www.wikidata.org/entity/Q28194726

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@ast

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@en

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@nl

type

label

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@ast

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@en

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@nl

prefLabel

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@ast

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@en

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@nl

P1433

Q28194726-79DA1328-FE6E-477C-A185-507866AF715B

P1476

Q28194726-A4E28977-EA62-4E68-94BC-E60240BE3848

P2093

Q28194726-01978111-81A7-4060-A8BC-0F53FBF49183

Q28194726-12D4A3E3-3F32-4C21-927D-8D18F26DC350

Q28194726-2CB132CC-E62D-4167-B76F-BBEF8296A9DA

Q28194726-589F8FC3-A031-400C-8CB6-4C2F450B3A6F

Q28194726-90C0AA4F-FD97-4223-9D3F-75A0F069AF3D

Q28194726-951762DC-B26E-4509-82D1-45B1F1B36000

Q28194726-B08F8ACA-E322-4C92-B3B0-D36EE3E59AFD

Q28194726-BAE81153-7569-4CE9-A562-2ED36916331E

Q28194726-D3EF6679-9808-49A6-AF31-C941AB55B72C

Q28194726-EC606A6C-206B-40EE-BDC7-646FF102DFD5

P304

Q28194726-319CE054-CD67-48F9-9E71-4BB998D05115

P31

Q28194726-1F78BE29-D614-4DE6-AF68-3D39D1F75DD3

P3181

Q28194726-2222F8CC-FFC5-4833-AE9E-B287DEC775F8

P356

Q28194726-52F30C83-F57A-4BE3-B490-F8AB9B153AB8

P407

Q28194726-0D120681-9956-4F57-8975-E473F33C1808

P433

Q28194726-49407DCD-70EB-4CFB-8A4D-29F65BBE954B

P478

Q28194726-92F438C9-20C2-4AB6-984C-22074EAD5B25

P50

Q28194726-2001E471-9640-4318-9E7B-4557124671D7

Q28194726-DBC04893-B2AE-48AB-BA4D-E0B7FF56AA1D

P577

Q28194726-2480092B-AB08-49F8-AC8F-86C7EDFA37B3

P698

Q28194726-9BE6CDF5-B136-4048-A5E7-18D121F4D885

P921

Q28194726-C1EAD6FB-86A7-43CD-835D-FAB1E57920FA

P3181

P356

01.CIR.0000051361.69808.3A

P1433

P1476

Selective COX-2 inhibition improves endothelial function in coronary artery disease

@en

P2093

Beat Michel

http://www.w3.org/2001/XMLSchema#string

David Hürlimann

http://www.w3.org/2001/XMLSchema#string

Frank Enseleit

http://www.w3.org/2001/XMLSchema#string

Georg Noll

http://www.w3.org/2001/XMLSchema#string

Lukas Spieker

http://www.w3.org/2001/XMLSchema#string

Markus Béchir

http://www.w3.org/2001/XMLSchema#string

Matthias Hermann

http://www.w3.org/2001/XMLSchema#string

Michel Neidhart

http://www.w3.org/2001/XMLSchema#string

Renate E Gay

http://www.w3.org/2001/XMLSchema#string

Rémy Chenevard

http://www.w3.org/2001/XMLSchema#string

P304

405-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3746450

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/01.CIR.0000051361.69808.3A

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Lüscher

Frank Ruschitzka

P577

2003-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12551863

http://www.w3.org/2001/XMLSchema#string

P921